Your AI-Trained Oncology Knowledge Connection!
Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.
The FDA approved the combination of dabrafenib and trametinib for patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer.
The FDA has approved subcutaneous rituximab (Rituxan Hycela) for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia.
Senate Republicans have introduced a healthcare bill that would revise many of the changes imposed by the Patient Protection and Affordable Care Act, cutting federal support for Medicaid and repealing the individual and employer mandates for having and providing insurance.
Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation with radical prostatectomy in patients with intermediate-risk prostate cancer.
Adrienne A. Phillips, MD, discussed the subtypes of adult T-cell lymphoma/leukemia, the challenges with treating them, and what community oncologists need to know about these patient populations.
Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.
Study results demonstrated that split-doses of gemcitabine and cisplatin as neoadjuvant chemotherapy for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.
Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.
A supplemental Biologics License Application has been submitted to the FDA for brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate with Takeda.
Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate of 16% in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial.
Lisa G. Roth, MD, discusses the challenges of treating adolescent and young adult patients with Hodgkin lymphoma and the benefits of having a multidisciplinary approach with this population.
Results from a blinded, independent data review confirmed previous results from the CABOSUN trial showing that treatment with cabozantinib (Cabometyx) extended progression-free survival compared with sunitinib (Sutent) for patients with previously untreated, intermediate- or poor-risk advanced renal cell carcinoma.
Seattle Genetics has stopped the phase III CASCADE trial of frontline vadastuximab talirine (SGN-CD33A) for patients with acute myeloid leukemia following a recommendation from an independent data monitoring committee.
Tsiporah B. Shore, MD, discusses some of these newer advancements related to stem cell transplantation and the challenges with including patients in ethnic populations.
Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.
Treatment with rituximab (Rituxan) plus lenalidomide (Revlimid) followed by maintenance therapy demonstrated promising clinical activity for patients with relapsed/refractory indolent non-Hodgkin's lymphoma, according to findings from the phase IIIb MAGNIFY study.
The European Commission has approved the rituximab (Rituxan) biosimilar Rixathon (GP2013) to treat patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
Phase III data from the ARIEL3 trial showed that rucaparib (Rubraca) improved progression-free survival versus placebo as a maintenance treatment for women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer.
The FDA has accepted a supplemental biologics license application for the use of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Daniel P. Petrylak, MD, discusses the KEYNOTE-045 results and the next steps with pembrolizumab (Keytruda) in urothelial carcinoma.
Regulatory actions have significantly reduced oncologists' pay in recent years, as part of the effort to improve value, but reforms are needed much higher up the drug distribution chain.
Lenvatinib (Lenvima) significantly improved overall survival in patients older than 65 years with radioiodine-refractory differentiated thyroid cancer.
Lurbinectedin (PM01183) induced a high rate of response as monotherapy and with doxorubicin or paclitaxel in patients with advanced endometrial cancer.
The FDA has approved daratumumab for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including a proteasome inhibitor and lenalidomide.
The PARP inhibitor olaparib demonstrated clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer in a recent study.
Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.
Bijal D. Shah, MD, discusses the current treatment paradigm of MCL, what therapies are moving through the pipeline at a rapid rate, the potential benefit with CAR T-cell therapy, and pivotal biomarker studies currently being conducted.
Ian W. Flinn, MD, PhD, discusses the 5-year update of the BRIGHT study in MCL and NHL.